FDA approval of first-in-class Aimovig set to transform the migraine market

This article is part of an ongoing blog series profiling the12 new, game-changing drugs predicted to achieve blockbuster status by 2022 in the 2018 edition of Drugs to Watch, the annual industry forecast and analysis from Clarivate Analytics. Read the full Drugs to Watch report here or follow the series for the latest updates. Approval […]

Migraine: a revolution in prevention

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. The migraine market has seen little movement for many years, with no new therapies entering the space either for acute treatment or […]